Effect of L-ornithine-L-aspertate (LOLA) on the Gut Microbiome (LOLAbiome)
Cirrhosis
About this trial
This is an interventional treatment trial for Cirrhosis
Eligibility Criteria
Inclusion Criteria: • Liver cirrhosis (clinical/radiological/histological diagnosis) Indication for LOLA use (covert or over hepatic encephalopathy, Grad 0-2)) Written informed consent Age 18 -100 years Exclusion Criteria: • Allergy to LOLA or its constituents, or to medications with a similar chemical structure (oral nutritional supplements are allowed when stable >/= 8 weeks before and during the study) Recent (</= 8 weeks) changes of the dose of the lactulose therapy for hepatic encephalopathy Rifaximin or any other antibiotic therapy within the past 4 weeks Intake of LOLA in the past four weeks before inclusion Intake of L-dopamine Renal insufficiency with a serum creatinine >3mg/dl Hepatocellular carcinoma BCLC D under best supportive care Inability to give informed consent Pregnancy or breastfeeding Participation in another interventional trial within the last 30 days
Sites / Locations
- Department of Internal Medicine, Medical University of GrazRecruiting
Arms of the Study
Arm 1
Experimental
L-ornithine-L-aspertate
L-ornithine-L-aspertate 18g per day